Sun Pharma buys Organon for $11.75B

Sun Pharmaceutical Industries said Monday it will buy Organon & Co. in an all-cash deal valued at $11.75 billion, including debt. (sunpharma.com) (sec.gov) Organon shareholders will receive $14 a share in cash under the merger agreement signed April 26, 2026, by Sun Pharma entities and Organon. (sec.gov) (organon.com) Sun Pharma and Organon said the boards of both companies approved the transaction, which still needs regulatory clearance and approval from Organon stockholders. (sunpharma.com) (organon.com) The acquisition would push Sun Pharma into the top 25 global pharmaceutical companies, with combined revenue of $12.4 billion, according to the companies. (organon.com) (sunpharma.com) Organon was spun out of Merck in 2021 and built its business around women’s health, biosimilars and a large portfolio of established medicines. (reuters.com) (organon.com) Sun Pharma said the tie-up would make it a top 3 company in global women’s health and the seventh-largest global biosimilar player. (organon.com) (fiercepharma.com) Reuters described the takeover as the largest overseas acquisition by an Indian pharmaceutical company, extending Sun Pharma’s push beyond low-margin generics. (reuters.com) (asia.nikkei.com) Sun Pharma shares rose more than 7% after the announcement, as investors bet the company could use Organon’s portfolio and distribution network to scale faster overseas. (cnbc.com) (reuters.com) Sun Pharma said the combined company would operate in 150 countries, with 18 large markets each generating more than $100 million in revenue. (sunpharma.com) If the deal closes, Sun Pharma will have turned a domestic generics leader into a much larger global drugmaker with a deeper position in women’s health and biosimilars. (organon.com) (reuters.com)